Skip to content
Screener

Evolus EOLS Cash & Equivalents

Cash & Equivalents at other companies

AbbVie logo
AbbVieABBV
$9.39B+81.5%

Other financials

Income statement

See full
Revenue$84.1M+21.2%
Gross profit$57.2M+26.2%
Operating income-$4.5M+55.5%
Net income-$8.1M+53.0%
EPS (diluted)-$0.12+55.6%

Balance sheet

See full
Total debt$164.8M+12.3%
Total equity-$30.9M-65.7%
Total assets$248.0M+8.4%

Cash flow

See full
Operating cash flow-$3.6M+85.5%
CapEx$50.0K-92.7%
Free cash flow-$3.6M+85.7%

Valuation

See full
Market cap$501.32M+31.4%
Enterprise value$620.96M+33.1%
P/S1.6×+0.2×

Profitability

See full
Gross margin66.7%-0.4pp
Operating margin-13.7%-1.9pp
Net margin-10.9%-3.7pp
FCF margin-9.6%-3.6pp

Returns & leverage

See full
Return on equity-472.6%-1,534pp
Debt / equity22.2×
Current ratio1.7×-0.6×

Where this comes from

Reported directly by Evolus in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The source filing: Evolus’s 10-Q, filed August 5, 2026. Open the filing →

Filed
Aug 5, 2026, 4:56 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-053468

FAQ

What is Evolus's cash & equivalents?
Evolus (EOLS) reported cash & equivalents of $45.17M in Q2 2026.
How has Evolus's cash & equivalents changed year-over-year?
Evolus's cash & equivalents decreased by 26.8% year-over-year, from $61.74M to $45.17M.
What is the long-term trend for Evolus's cash & equivalents?
Over 5 years (2020 to 2025), Evolus's cash & equivalents has grown at a -12.1% compound annual growth rate (CAGR), from $102.56M to $53.83M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Ask your AI about Evolus's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude